Description

Cencora Takeover Twist: How EyeSouth Could Fuel A Specialty Pharma Surge!

Cencora has entered a new phase in its healthcare-services strategy with the signing of a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, a move that would fold EyeSouth’s affiliated retina physicians into Retina Consultants of America, or RCA. The announcement came as the company reaffirmed fiscal 2026 guidance and then, shortly after, reported a strong first quarter of fiscal 2026 marked by 12% adjusted operating income growth, 9% adjusted diluted EPS growth, and increased full-year operating income guidance following the closing of its OneOncology transaction. Management’s commentary also offered a useful read-through for the EyeSouth deal: Cencora has been explicit that pharmaceutical-centric management services organizations, or MSOs, are central to its strategy, and RCA has already outperformed expectations in volume, research, and physician additions. Against that backdrop, adding EyeSouth’s retina platform would not be a standalone financial transaction.